◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

Vaxil Bio Ltd.

Financial Statements (IFRS) · Amounts in CAD
5 10 All
Income Statement
Balance Sheet
Cash Flow
Line Item Q3 2025Sep 30, 2025 Q2 2025Jun 30, 2025 Q1 2025Mar 31, 2025 Q4 2024Dec 31, 2024 Q3 2024Sep 30, 2024
Total Revenue 0.00 0.00 0.00 0.00 0.00
Operating Revenue 0.00 0.00 0.00 0.00 0.00
Selling General And Administration 32,000 37,000 70,000 31,000 44,000
General And Administrative Expense 32,000 37,000 70,000 31,000 44,000
Research And Development -- -- 4,000 2,000 3,000
Operating Expense 32,000 37,000 74,000 33,000 44,000
Operating Income -32,000 -37,000 -74,000 -33,000 -44,000
EBIT -32,000 -37,000 -74,000 -33,000 -44,000
Interest Income 12,000 73,000 4,000 10,000 8,000
Interest Income Non Operating 12,000 73,000 4,000 10,000 8,000
Net Interest Income 12,000 73,000 4,000 10,000 8,000
Special Income Charges -- -- -- 0.00 0.00
Pretax Income -20,000 36,000 -70,000 -23,000 -36,000
Tax Effect Of Unusual Items 0.00 0.00 0.00 0.00 0.00
Net Income From Continuing And Discontinued Operation -20,000 42,000 -70,000 -22,000 -49,000
Net Income From Continuing Operation Net Minority Interest -20,000 36,000 -70,000 -22,000 -36,000
Net Income Including Noncontrolling Interests -20,000 42,000 -70,000 -23,000 -49,000
Net Income Common Stockholders -20,000 42,000 -70,000 -22,000 -49,000
Net Income -20,000 42,000 -70,000 -22,000 -49,000
EBITDA -32,000 -37,000 -74,000 -33,000 -44,000
Normalized EBITDA -32,000 -37,000 -74,000 -33,000 -44,000
Basic EPS -0.01 0.02 -0.03 -- -0.02
Diluted EPS -0.01 0.02 -0.03 -- -0.02
Basic Average Shares 2.7M 2.7M 2.7M -- 2.7M
Diluted Average Shares 2.7M 2.7M 2.7M -- 2.7M
Total Unusual Items -- -- -- 0.00 0.00
Total Unusual Items Excluding Goodwill -- -- -- 0.00 0.00
Tax Rate For Calcs 0.00 0.15 0.00 0.00 0.00
Normalized Income -20,000 36,000 -70,000 -22,000 -36,000
Diluted NI Availto Com Stockholders -20,000 42,000 -70,000 -22,000 -49,000
Gain On Sale Of Ppe -- -- -- 0.00 0.00
Insurance And Claims -- -- 5,000 7,000 4,000
Net Income Continuous Operations -20,000 36,000 -70,000 -23,000 -36,000
Net Income Discontinuous Operations 0.00 6,000 -- -- -13,000
Net Non Operating Interest Income Expense 12,000 73,000 4,000 10,000 8,000
Other Gand A 32,000 37,000 63,000 13,000 44,000
Rent And Landing Fees -- -- 2,000 11,000 3,000
Rent Expense Supplemental -- -- 2,000 11,000 3,000
Salaries And Wages 0.00 0.00 0.00 0.00 0.00
Total Expenses 32,000 37,000 74,000 33,000 44,000
Total Operating Income As Reported -32,000 -37,000 -74,000 -32,000 -44,000
Line Item Q3 2025Sep 30, 2025 Q2 2025Jun 30, 2025 Q1 2025Mar 31, 2025 Q4 2024Dec 31, 2024 Q3 2024Sep 30, 2024
Cash And Cash Equivalents 447,000 347,000 403,000 448,000 535,000
Cash Cash Equivalents And Short Term Investments 447,000 347,000 403,000 448,000 535,000
Cash Financial -- -- -- -- 535,000
Other Short Term Investments -- -- -- -- --
Accounts Receivable 12,000 12,000 15,000 -- 27,000
Receivables 156,000 278,000 281,000 273,000 285,000
Prepaid Assets -- -- -- 12,000 --
Current Assets 603,000 625,000 684,000 733,000 820,000
Investments And Advances 72,000 72,000 -- -- --
Total Non Current Assets 72,000 72,000 0.00 0.00 0.00
Total Assets 675,000 697,000 684,000 733,000 820,000
Payables And Accrued Expenses 8,000 6,000 40,000 17,000 82,000
Current Liabilities 8,000 6,000 40,000 17,000 82,000
Total Non Current Liabilities Net Minority Interest 0.00 0.00 0.00 0.00 0.00
Total Liabilities Net Minority Interest 8,000 6,000 40,000 17,000 82,000
Common Stock 16.1M 16.1M 16.1M 16.1M 16.1M
Capital Stock 16.1M 16.1M 16.1M 16.1M 16.1M
Retained Earnings -19.6M -19.6M -19.6M -19.5M -19.5M
Gains Losses Not Affecting Retained Earnings 4.2M 4.2M 4.2M 4.2M 4.2M
Other Equity Adjustments 4.2M 4.2M 4.2M 4.2M 4.2M
Common Stock Equity 667,000 691,000 644,000 716,000 738,000
Stockholders Equity 667,000 691,000 644,000 716,000 738,000
Total Equity Gross Minority Interest 667,000 691,000 644,000 716,000 738,000
Total Capitalization 667,000 691,000 644,000 716,000 738,000
Net Tangible Assets 667,000 691,000 644,000 716,000 738,000
Tangible Book Value 667,000 691,000 644,000 716,000 738,000
Working Capital 595,000 619,000 644,000 716,000 738,000
Invested Capital 667,000 691,000 644,000 716,000 738,000
Share Issued 2.7M 2.7M 2.7M 2.7M 2.7M
Ordinary Shares Number 2.7M 2.7M 2.7M 2.7M 2.7M
Notes Receivable 144,000 266,000 266,000 266,000 258,000
Taxes Receivable -- -- -- 7,000 --
Line Item Q3 2025Sep 30, 2025 Q2 2025Jun 30, 2025 Q1 2025Mar 31, 2025 Q4 2024Dec 31, 2024 Q3 2024Sep 30, 2024
Operating Cash Flow -28,000 -52,000 -47,000 -84,000 -43,000
Cash Flow From Continuing Operating Activities -28,000 -52,000 -47,000 -84,000 -43,000
Stock Based Compensation 0.00 0.00 0.00 0.00 0.00
Change In Working Capital 4,000 -23,000 27,000 -52,000 1,000
Changes In Account Receivables -- -- 4,000 -- --
Change In Receivables 7,000 7,000 4,000 9,000 -4,000
Change In Payables And Accrued Expense -3,000 -30,000 23,000 -61,000 5,000
Other Non Cash Items -12,000 -73,000 -4,000 -10,000 --
Investing Cash Flow 127,000 -- -- 0.00 0.00
Cash Flow From Continuing Investing Activities 127,000 -- -- 0.00 0.00
Effect Of Exchange Rate Changes 1,000 -2,000 2,000 -3,000 2,000
Changes In Cash 99,000 -54,000 -47,000 -84,000 -56,000
Beginning Cash Position 347,000 403,000 448,000 535,000 589,000
End Cash Position 447,000 347,000 403,000 448,000 535,000
Free Cash Flow -28,000 -52,000 -47,000 -84,000 -43,000
Cash Flow From Discontinued Operation 0.00 -- -- -- -13,000
Net Income From Continuing Operations -20,000 44,000 -70,000 -22,000 -36,000
Net Other Investing Changes -- -- -- 0.00 0.00
NEWS
Loading news...
TRENDING
Loading...